Current trends in management of pediatric asthma

Respiratory Care

Volumn 48, Issue 3, 2003, Pages 194-205

  Kercsmar, Carolyn M ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Acute asthma; Ambulatory care; Asthma; Emergency management; Pediatric

Indexed keywords

ADRENALIN; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID DERIVATIVE; CROMOGLYCATE DISODIUM; DEXAMETHASONE; FLUTICASONE; FORMOTEROL; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVALBUTEROL; MAGNESIUM SULFATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MONTELUKAST; NEDOCROMIL; PREDNISOLONE; PREDNISONE; SALBUTAMOL; SALMETEROL; STEROID; THEOPHYLLINE; TRIAMCINOLONE ACETONIDE; ZAFIRLUKAST; ZILEUTON; ANTIASTHMATIC AGENT;

AMBULATORY CARE; ASTHMA; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; EMERGENCY WARD; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE QUALITY; HOSPITAL PATIENT; HUMAN; MEDICAL ASSESSMENT; MEDICAL PRACTICE; NEBULIZER; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; SAFETY; SINGLE DRUG DOSE; ARTIFICIAL VENTILATION; CHILD; CLINICAL PATHWAY; DISEASE MANAGEMENT; EMERGENCY HEALTH SERVICE; METHODOLOGY; PEDIATRICS; REVIEW; STANDARD; UNITED STATES;

AMBULATORY CARE; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CRITICAL PATHWAYS; DISEASE MANAGEMENT; EMERGENCY MEDICAL SERVICES; EMERGENCY SERVICE, HOSPITAL; HUMANS; PEDIATRICS; QUALITY OF HEALTH CARE; RESPIRATORY THERAPY; UNITED STATES;

EID: 0038343360     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (79)

1. American Academy of Allergy, Asthma, and Immunology. Pediatric asthma: predicting best practice. AAAAI. 1999:p2-4.
2. Kwan-Gett TS, Lozano P, Mullin K, Marcus EK. One-year experience with an inpatient asthma clinical pathway. Arch Pediatr Adolesc Med 1997;151(7):684-689.
3. McDowell KM, Chatburn RL, Myers TR, O'Riordan MA, Kercsmar CM. A cost saving algorithm for children hospitalized for status asthmaticus. Arch Pediatr Adolesc Med 1998;152(10):977-984.
4. Craven D, Kercsmar CM, Myers TR, O'Riordan MA, Golonka G, Moore S. Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma. J Pediatr 2001;138(1):51-58.
5. Myers TR, Kercsmar CM. Does nebulizer brand make a clinical difference? (abstract) Eur Resp J 1999;14(S30):S12-13.
6. Carl JC, Myers TR, Kercsmar CM. Comparison of levalbuterol and racemic albuterol for treatment of acute asthma in pediatric patients (abstract). Chest 2001;120 4 Suppl:137S.
7. Johnson KB, Blaisdell CJ, Walker A, Eggelston P. Effectiveness of a clinical pathway for inpatient asthma management. Pediatrics 2000;106(5):1006-1012.
8. Myers TR, Chatburn RL, Kercsmar CM. A pediatric asthma unit staffed by respiratory therapists demonstrates positive clinical and financial outcomes. Respir Care 1998;43(1):22-29.
9. Kelly CS, Andersen CL, Pestian JP, Wenger AD, Finch AB, Strope GL, Luckstead EF. Improved outcomes for hospitalized asthmatic children using a clinical pathway. Ann Allergy Asthma Immunol 2000;84(5):509-516.
10. Wazeka A. Valacer DJ, Cooper M, Caplan DW, DiMaio M. Impact of a pediatric asthma clinical pathway on hospital cost and length of stay. Pediatr Pulmonol 2001;32(3):211-216.
11. Bailey R, Weingarten S, Lewis M, Mohsenifar Z. Impact of clinical pathways and practice guidelines on the management of acute exacerbations of bronchial asthma. Chest 1998;113(1):28-33.
12. Nelson HS. β-adrenergic bronchodilators. N Engl J Med 1995;333(8):499-506.
13. DeNicola LK, Monem GF, Gayle MO, Kissoon N. Treatment of critical status asthmaticus in children. Pediatr Clin North Am 1994;41(6):1293-1324.
14. Schuh S, Parkin P, Rajan A, Canny G, Healy R, Rieder M, et al. High-versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma. Pediatrics 1989;83(4):513-518.
15. Robertson CF, Smith F, Beck R, Levison H. Response to frequent low doses of nebulized salbutamol in acute asthma. J Pediatr 1985;106(4):672-674.
16. Guidelines for the diagnosis and management of asthma. Expert panel Report 2. NIH publication No. 97-4051. Bethesda MD: 1997.
17. Schuh S, Reider MJ, Canny G, Pender E, Forbes T, Tan YK, et al. Nebulized albuterol in acute childhood asthma: comparison of two doses. Pediatrics 1990;86(4):509-513.
18. Coates AL, Ho SL. Drug administration by jet nebulization. Pediatr Pulmonol 1998;26(6):412-423.
19. Emerman CL, Cydulka RK, McFaden ER. Comparison of 2.5 vs 7.5mg of inhaled albuterol in the treatment of acute asthma. Chest 1999;115(1):92-96.
20. Shrestha M, Bidadi K, Gourlay S, Hayes J. Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults. Chest 1996;110(1):42-47.
21. Papo MC, Frank J, Thompson AE. A prospective randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med 1993;21(10):1479-1486.
22. Everard ML. Studies using radiolabelled aerosols in children. Thorax 1994;49(12):1259-1266.
23. Everhard ML, Clark AR, Milner AD. Drug delivery from jet nebulizers. Arch Dis Child 1992;67(5):586-591.
24. Schuh S, Johnson DW, Stephens D, Callahan S, Winders P, Canny GJ. Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma. J Pediatr 1999;135(1):22-27.
25. Newhouse MT. Emergency department management of life-threatening asthma: are nebulizers obsolete? Chest 1993;103(3):661-662.
26. Chou KJ, Cunningham SJ, Crain EF. Metered-dose inhalers with spacers vs nebulizers for pediatric asthma. Arch Pediatr Adolesc Med 1995;149(2):201-205.
27. Amirav I, Newhouse MT. Metered dose inhaler accessory devices in acute asthma: efficacy and comparison with nebulizers: a literature review. Arch Pediatr Adolesc Med 1997;151(9):876-882.
28. Amirav I, Newhouse MT. Aerosol therapy with valved holding chambers in young children: importance of the facemask seal. Pediatrics 2001;108(2):389-394.
29. Wildhaber JH, Dore ND, Wilson JM, Devadason SG, LeSouef PN. Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999;135(1):28-33.
30. Penn RB, Frielle T, McCullough JR, Aberg G, Benovic JL. Comparison of R-, S-, and RS-albuterol interaction with human β1-and β2-adrenergic receptors. Clin Rev Allergy Immunol 1996;14(1):37-45.
31. Mazzoni L, Naef R, Chapman ID, Morley J. Hyperresponsiveness of the airways following exposure of guinea-pigs to racemic mixtures and distomers of β2-selective sympathomimetics. Pulm Pharmacol 1994;7(6):367-376.
32. Baramki D, Koester J, Anderson AJ. Borish L. Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol 2002;109(3):449-454.
33. Cockcroft DW, O'Byrne PM, Swystun VA, Bhagat R. Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J Allergy Clin Immunol 1995;96(1):44-49.
34. Mitra S, Ugur M, Ugur O, Goodman HM, McCullough JR, Yamaguchi H. (S)-albuterol increases intracellular free calcium by muscarinic receptor activation and a phopholipase C dependent mechanism in airway smooth muscle. Molecular Pharmacol 1998;53(3):347-354.
35. Perrrin-Fayolle M, Blum PS, Morley J, Grosclaude M, Chambe MT. Differential responses of asthmatic airways to enantiomers of albuterol. Clin Rev Allergy Immunol 1996;14(1):139-147.
36. Page CP, Morley J. Contrasting properties of albuterol stereoisomers. J Allergy Clin Immunol 1999;104(2 Pt 2):S31-S41.
37. Milgrom H, Skoner DP, Bensch G, Kim KT, Claus R, Baumgartner RA. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001;108(6):938-945.
38. Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids (Cochrane Review). In: The Cochrane Library, Issue 4 2002. Oxford: Update Software. Available at http://www.updatesoftware.com/abstracts/titlelist.htm. (accessed Jan 8, 2003)
39. Schuh S, Reisman J, Alshehri M, Dupuis A, Corey M, Arseneault R, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med 2000;343(10):689-694.
40. Edmonds ML, Camargo CA Jr, Pollack CV Jr, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma (Cochrane Review). In: The Cochrane Library, Issue 4 2002. Oxford: Update Software. Available at http://www.updatesoftware.com/abstracts/titlelist.htm. (accessed Jan 8, 2003)
41. Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma Am J Respir Crit Care Med 1998;157(3 Pt 1):698-703.
42. Sung L, Osmond MH, Klassen TP. Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma. Acad Emerg Med 1998;5(3):209-213.
43. Wilson NM, Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroid at home. Arch Dis Child 1990;65(4):407-410.
44. Garrett J, Williams S, Wong C, Holdaway D. Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid. Arch Dis Child 1998;79(1):12-17.
45. Schleimer RP. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma. Am Rev Respir Dis 1990;141(2 Pt 2):S59-S69.
46. Qureshi F, Zaritsky A, Poirier MP. Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma. J Pediatr 2001;139(1):20-26.
47. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001;163(7):1693-1722.
48. Busse WW, Lemanske RF. Asthma. N Engl J Med 2001;344(5):350-362.
49. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000;356(9248):2144-2148.
50. Agertoft L, Pederson S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000;343(15):1064-1069.
51. Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000;343(15):1054-1063.
52. Allen DB, Bronsky EA, LaForce CF, Nathan RA, Tinkelman DG, Vandewalken ML, Konig P, and the Fluticasone Propionate Asthma Study Group. Growth in asthmatic children treated with fluticasone propionate. J Pediatr 1998;132(3 Pt 1):472-477.
53. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001;345(13):941-947.
54. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998;280(6):539-543.
55. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995;332(13):868-875.
56. Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty TL, Rennard S. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adultpatients with chronic asthma. J Allergy Clin Immunol 1998;101(4 Pt 1):457-463.
57. Pederson S, Hansen OR. Budesonide treatment of moderate and severe asthma in children: a dose response study. J Allergy Clin Immunol 1995;95(1 Pt 1):29-33.
58. Inman MD, Watson RM, Rerechich T, Gauvreau GM, Lutsky BN, Stryszak P, O'Byrne PM. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med 2001;164(4):569-574.
59. Swystun VA, Bhagat R, Kalra S, Jennings B, Cockcroft DW. Comparison of 3 different doses of budesonide and placebo on the early asthmatic response to inhaled allergen. J Allergy Clin Immunol 1998 Sep;102(3):363-367.
60. Jatakanon A, Kharitonov S, Lim, S Barnes PJ. Effect of differing dose of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999;54(2):108-114.
61. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001;323(7307):253-256.
62. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Pineiro A, Wei LX, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999;130(6):487-495.
63. Chan MT, Leung DY, Szefler SJ, Spahn JD. Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma. J Allergy Clin Immunol 1998;101(5):594-601.
64. Kerrebijn KF, van Essen-Zandvliet EE, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and β-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987;79(4):653-659.
65. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002;109(3):410-418.
66. Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF, and the Dutch Paediatric Asthma Study Group. Addition of salmeterol versus doubling the dose of beclomethsone in children with asthma. Am J Respir Crit Care Med 1998;158(1):213-219.
67. Bisgaard H. Long-acting β2-agonists in management of childhood asthma: a critical review of the literature. Pediatr Pulmonol 2000;29(3):221-234.
68. Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997;99(5):655-659.
69. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J 2002;19(1):182-191.
70. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153(5):1481-1488.
71. Greening AP, Wind P, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344(8917):219-224.
72. van Noord JA, Schreurs AJ, Mol SJ, Mulder PG. Addition of salmeterol versus doubling the dose of fluticsone proionate in patients with mild to moderate asthma. Thorax 1999;54(3):207-212.
73. Meijer GG, Postma DS, Mulder PGH, van Aalderen WM. Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids. Am J Respir Crit Care Med 1995;152(6 Pt 1):1887-1892.
74. Russell G, Williams DA, Weller P, Price JF. Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol 1995;75(5):423-428.
75. Evans DJ, Taylor DA, Zetterstrom O, Fan Chung K, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337(20):1412-1418.
76. Bisgaard H. Leukotriene modifiers in pediatric asthma management. Pediatrics 2001;107(2):381-390.
77. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999;Dec;160(6):1862-1868.
78. Lofdahl CG, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF, et al. Randomized, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999;319(7202):87-90.
79. Simons FER, Villa JR, Lee BW, Teper AM, Lyttle B, Aristizabal G, et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr 2001;138(5):694-698.